Tadalafil (Generic) vs Alprostadil (Caverject/MUSE): Side-Effect Profile Head-to-Head

How These Drugs Work Differently and Why That Shapes Their Side Effects

Tadalafil is an oral PDE5 inhibitor that circulates systemically, blocking phosphodiesterase-5 in penile smooth muscle but also in vascular beds throughout the body. This systemic distribution explains why its adverse effects (headache, flushing, nasal congestion) appear far from the target organ. Alprostadil is prostaglandin E1 delivered directly to erectile tissue via intracavernosal injection (Caverject) or intraurethral pellet (MUSE), producing a local erection with minimal systemic absorption.

The pharmacokinetic distinction is stark. Tadalafil's 17.5-hour half-life means side effects can persist for 24-36 hours after a single dose 1. Alprostadil is metabolized locally within 60 minutes, so its adverse effects resolve faster but are more intense at the site of action. A 2002 integrated analysis of tadalafil trials involving over 4,000 men confirmed that most systemic adverse events peaked within 12 hours and declined steadily as plasma concentrations fell 1.

Tadalafil (Generic): Complete Side-Effect Profile

The most common adverse events in tadalafil clinical trials are headache (11-15%), dyspepsia (4-12%), back pain (4-9%), myalgia (1-5%), nasal congestion (3-5%), and flushing (3-4%) 1. Back pain and myalgia distinguish tadalafil from sildenafil and vardenafil. These musculoskeletal symptoms typically appear 12-24 hours post-dose and resolve within 48 hours without intervention.

Serious adverse events are uncommon. In the Brock et al. integrated analysis (N=4,135), discontinuation due to adverse events occurred in only 3.1% of tadalafil-treated men versus 1.4% on placebo 1. No cases of ischemic optic neuropathy were attributed to tadalafil in the key program, though post-marketing surveillance has identified rare reports. Cardiovascular event rates did not differ between tadalafil and placebo groups, a finding confirmed by a 2006 meta-analysis published in the Journal of Sexual Medicine covering over 13,000 patient-years of exposure 2.

Daily tadalafil (2.5-5 mg) produces lower peak plasma concentrations than on-demand dosing (10-20 mg), resulting in fewer headaches and less dyspepsia at steady state. The FDA label reports headache at 6% with daily 5 mg versus 15% with on-demand 20 mg 3.

The absolute contraindication is concurrent nitrate use. The combination can produce severe hypotension. Alpha-blocker co-administration requires dose stabilization and careful titration 3.

Alprostadil (Caverject/MUSE): Complete Side-Effect Profile

Penile pain dominates the alprostadil safety profile. In the landmark Linet et al. NEJM trial (N=296), 29% of men using intracavernosal alprostadil reported penile pain, with most rating it mild to moderate on visual analog scales 4. Pain typically diminishes with repeated use as patients refine injection technique.

MUSE (intraurethral alprostadil) carries a different local side-effect signature: urethral burning or pain in 24-33% of users, minor urethral bleeding in 5%, and dizziness in 2-4% from limited systemic absorption through urethral mucosa 5.

Prolonged erection (defined as lasting 4-6 hours) occurred in 4-5% of Caverject users in the Linet trial, and priapism (exceeding 6 hours) in approximately 1% 4. This risk mandates office titration before home use and patient education on when to seek emergency detumescence. Penile fibrosis, including Peyronie's-like plaque formation, develops in 3-8% of men using intracavernosal injections beyond 12-18 months, based on prospective follow-up data 6.

Because alprostadil acts locally, it has essentially no systemic drug interactions. Men taking nitrates, alpha-blockers, or multiple antihypertensives can use alprostadil without hemodynamic concern. This is the primary clinical advantage for patients who cannot take PDE5 inhibitors.

Direct Comparison: Incidence Rates Side by Side

No large randomized trial has directly compared tadalafil and alprostadil head-to-head for adverse events. The comparison below synthesizes data from their respective registration programs and long-term extension studies.

For systemic effects, tadalafil produces headache in 11-15% of users while alprostadil produces headache in <1%. Flushing occurs in 3-4% with tadalafil versus essentially 0% with alprostadil. Dyspepsia affects 4-12% of tadalafil users and is not reported with alprostadil. Back pain (4-9% with tadalafil) does not occur with alprostadil. Dizziness appears in 1-2% of tadalafil users and 2-4% of MUSE users (from transient systemic absorption) 1 4.

For local effects, the pattern reverses. Penile pain is not associated with tadalafil but occurs in 29-50% of Caverject users. Prolonged erection risk is <0.1% with tadalafil versus 4-5% with Caverject. Urethral bleeding does not occur with tadalafil but affects 5% of MUSE users. Penile fibrosis is irrelevant with tadalafil but develops in 3-8% of long-term injection users 4 6.

The American Urological Association 2018 guidelines note that "PDE5 inhibitors remain first-line pharmacotherapy for ED given their favorable risk-benefit profile and ease of administration," with intracavernosal injection reserved for PDE5 non-responders or men with contraindications 7.

Severity and Patient Impact: Which Side Effects Matter More?

Raw incidence numbers do not capture the lived experience of these drugs. Tadalafil's headache, while common, is typically mild (paracetamol-responsive) and diminishes with continued use. The 2002 Brock analysis noted that headache led to discontinuation in only 1.1% of all tadalafil users 1. Most men tolerate it easily.

Alprostadil's penile pain is a different matter. While also rated "mild" on formal scales, pain at the site of sexual activity creates a psychological barrier that affects willingness to continue treatment. Long-term adherence data suggest 40-50% of men prescribed intracavernosal injections discontinue within 12 months, with pain cited as the leading reason 8. The fear of priapism adds additional anxiety.

A crossover preference study published in Urology found that among men who had tried both oral PDE5 inhibitors and intracavernosal alprostadil, 71% preferred oral therapy primarily due to convenience and absence of injection-site pain, while 29% preferred alprostadil due to more reliable erections 9.

Who Should Avoid Each Drug Based on Side-Effect Risk

Tadalafil should be avoided in men taking organic nitrates (nitroglycerin, isosorbide mononitrate/dinitrate) due to the risk of synergistic hypotension. Men with recent stroke or MI (within 90 days), unstable angina, or NYHA class III-IV heart failure should not use any PDE5 inhibitor per AUA guidelines 7. Those with known hypersensitivity to PDE5 inhibitors or concurrent use of potent CYP3A4 inhibitors at high doses require dose adjustment or avoidance.

Alprostadil should be avoided in men with sickle cell trait or disease, polycythemia, thrombocythemia, or conditions predisposing to priapism. Men with penile anatomic deformities (severe curvature, cavernosal fibrosis, Peyronie's plaques) are at higher risk of fibrosis progression with repeated injections 5. Anticoagulated patients may experience more bleeding at the injection site but are not contraindicated.

The practical clinical implication: men who fail or cannot use tadalafil due to cardiovascular contraindications are often ideal candidates for alprostadil, precisely because it lacks systemic hemodynamic effects.

Managing Side Effects in Clinical Practice

For tadalafil, headache management includes dose reduction (from 20 mg to 10 mg on-demand, or switching to daily 2.5-5 mg), pre-treatment with acetaminophen, and adequate hydration. Back pain responds to NSAIDs and typically resolves within 48 hours. Dyspepsia improves when the drug is taken with food rather than on an empty stomach 3.

For alprostadil injection pain, strategies include slower injection speed (over 5-10 seconds), using a 30-gauge needle, adding 2% lidocaine to the injection mixture (off-label but widely practiced), and applying topical anesthetic 10 minutes beforehand. Prolonged erections lasting 2-4 hours can often be managed at home with oral pseudoephedrine (60 mg) and ice packs; erections exceeding 4 hours require aspiration and phenylephrine injection in an emergency setting 10.

For MUSE-specific urethral discomfort, voiding before insertion to moisten the urethra and remaining upright for 10 minutes post-insertion improves drug distribution and may reduce burning.

Long-Term Safety: What Happens After Years of Use

Tadalafil's long-term safety record is extensive. A 2-year open-label extension study (N=1,173) showed no increase in adverse event rates over time, no tachyphylaxis, and no emergent cardiovascular safety signals 11. The most significant long-term consideration is that daily tadalafil at 5 mg has been FDA-approved since 2008 for both ED and BPH/LUTS, reflecting confidence in chronic-use safety.

Alprostadil's long-term concern centers on fibrosis. Prospective registry data show that corporal fibrosis develops in approximately 5-7% of men using Caverject for over 18 months, with the risk correlating to injection frequency (more than twice weekly) and technique errors (injecting into the same site repeatedly) 6. Regular penile examination every 3-6 months is recommended for long-term injection users.

Neither drug has demonstrated carcinogenicity or reproductive toxicity in long-term surveillance. Both are Category B in pregnancy considerations (relevant only for female partners using MUSE with condom protection recommended).

Switching Between Tadalafil and Alprostadil

Men who develop intolerable side effects on one agent can transition to the other without a washout period. The AUA guideline explicitly supports sequential pharmacotherapy: start with PDE5 inhibitors, then escalate to intracavernosal or intraurethral alprostadil if oral therapy fails or is contraindicated 7.

Combination therapy (low-dose tadalafil plus MUSE or low-dose Caverject) is used off-label in refractory cases. A small randomized trial (N=42) found that tadalafil 10 mg combined with MUSE 500 mcg produced superior rigidity versus either agent alone, without additive systemic side effects 12.

The Linet et al. trial specifically enrolled PDE5 non-responders and demonstrated that approximately 70% achieved erections sufficient for intercourse with alprostadil, confirming its role as rescue therapy when oral agents produce unacceptable side effects or insufficient efficacy 4.

Tadalafil daily dosing at 5 mg costs $15-45/month for generic formulations in 2026, while Caverject runs $40-80 per injection and MUSE approximately $30-60 per pellet, making side-effect tolerance a cost consideration as well.